DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06256419

RecruitingPhase NA

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

Assets

Exenatide / GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Enrollment

300

estimated

Study population

Type 2 diabetes

Key I/E criteria

•BMI 20-35•HbA1c 7-12%

Primary endpoints

•HbA1c, change•To identify and evaluate the variable factors influencing GLP-1 RA efficacy•Genotype identification

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06256419
Org study IDXYFY2023-KL479-01

Timeline

Milestones

Study start2024-01-01actual
Study first posted2024-02-13actual
Last update posted2025-09-18actual
Primary completion2028-01-31estimated
Study completion2028-01-31estimated

Assets

Investigational agents

ExenatideGLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age25 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. a diagnosis of T2DM

2. a body mass index (BMI) of 20-35 kg/m2

3. an HbA1c of 7.0%-12%, an age of 25-70 years

4. required data available at baseline and 6 months after GLP-1RA therapy.

Exclusion criteria

1. Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis

2. patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months

3. those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Glycemic / diabetes
1
Safety / tolerability / PK
1

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Change from baseline HbA1c and baseline weight at 6 month

Time frame:6 month after GLP-1 RA treatment

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment

Time frame:6 months after GLP-1 RA treatment

descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

To identify and evaluate the variable factors influencing GLP-1 RA efficacy

Time frame:1 month after sample integration

descriptive

Primary/protocol endpoint/low confidence

Genotype identification in patients with T2DM

Time frame:1 month after sample collecting

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.